In particular the triacylated lipopeptide outer surface protein A (OspA) of Borrelia burgdorferi, which is a TLR-1/2 agonist, has been previously clinically used as a vaccine against Lyme disease with minor side effects (reviewed in [73]). The gene discussed is TLR1; the disease is Lyme disease.